ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 79 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,406,691 | -40.4% | 893,668 | -23.5% | 0.12% | -29.9% |
| Q2 2023 | $9,067,312 | +15.7% | 1,168,468 | -15.0% | 0.16% | +6.5% |
| Q1 2023 | $7,834,468 | -17.3% | 1,374,468 | -14.5% | 0.15% | -14.9% |
| Q4 2022 | $9,468,576 | +41.7% | 1,607,568 | -23.0% | 0.18% | +46.0% |
| Q3 2022 | $6,680,000 | -28.6% | 2,087,568 | 0.0% | 0.12% | -26.6% |
| Q2 2022 | $9,352,000 | -16.1% | 2,087,568 | 0.0% | 0.17% | -6.6% |
| Q1 2022 | $11,148,000 | -67.6% | 2,087,568 | -10.7% | 0.18% | -59.0% |
| Q4 2021 | $34,362,000 | -29.7% | 2,337,574 | 0.0% | 0.44% | -17.7% |
| Q3 2021 | $48,879,000 | +18.2% | 2,337,574 | 0.0% | 0.54% | +28.5% |
| Q2 2021 | $41,352,000 | -27.8% | 2,337,574 | 0.0% | 0.42% | -21.9% |
| Q1 2021 | $57,271,000 | -42.1% | 2,337,574 | -20.0% | 0.54% | -38.2% |
| Q4 2020 | $98,909,000 | +35.3% | 2,921,967 | 0.0% | 0.86% | -5.9% |
| Q3 2020 | $73,078,000 | -25.9% | 2,921,967 | 0.0% | 0.92% | -33.8% |
| Q2 2020 | $98,558,000 | – | 2,921,967 | – | 1.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |